Company Overview
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Recent Developments
- Dec 2025 Revenue of $1.98M (-82.3% YoY); net profit $-9.63M.
- Trailing 12 Months Year-on-year growth — revenue -69.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -11.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -11.64% |
| 1 Year: | -69.50% |
Stock Price Performance
| 1 Year: | -21.72% |
| 6 Months: | -70.05% |
| 3 Months: | +15.69% |
| 1 Month: | +10.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)61.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -11.6% CAGR over 5 years.
- Trading 79.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LPCN Lipocine Inc. PHARMA | 2.36 | -1.28 | $19.46M | 0.00% | -71.64% | -60.94% | -11.64% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 54.99K | - | 500.00K | - | 54.99K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -2.97M | -4.28M | -6.43M | -4.70M | -7.07M | -5.82M | -3.29M | -3.02M | -4.91M | -6.14M | -4.77M | -5.40M | -2.64M | -3.16M | -2.35M | -3.17M | -3.13M | -3.35M | -2.98M | -4.60M | -4.22M | -4.38M | - | -3.11M | -2.99M | -3.53M | -3.13M | -3.53M | -2.90M | -4.34M | -3.96M | -7.04M | 3.22M | -3.29M | -2.63M | -2.09M | -2.40M | -3.36M | -3.85M | -2.84M |
| Net Income | -2.96M | -4.25M | -6.37M | -4.63M | -7.01M | -5.76M | -3.24M | -2.97M | -4.86M | -6.09M | -4.70M | -5.33M | -2.72M | -3.26M | -2.46M | -3.23M | -3.22M | -3.43M | -3.06M | -5.77M | -6.37M | -4.31M | - | -3.37M | -6.81M | -3.08M | -3.49M | -2.63M | -2.41M | -3.87M | -3.55M | -6.65M | 3.51M | -3.07M | -2.22M | -1.86M | -2.21M | -3.19M | -3.67M | -2.62M |
| Diluted EPS | -0.23 | -0.26 | -0.35 | -0.25 | -0.38 | -0.32 | -0.18 | -0.16 | -0.26 | -0.31 | -0.22 | -0.25 | -0.13 | -0.15 | -0.12 | -0.15 | -0.14 | -0.14 | -0.12 | -0.14 | -0.13 | -0.07 | - | -0.04 | -0.08 | -0.04 | -0.04 | -0.61 | -0.52 | -0.76 | -0.68 | -1.27 | 0.66 | -0.56 | -0.44 | -0.35 | -0.41 | -0.59 | -0.54 | -0.32 |
| R&D Expense | 1.92M | 3.16M | 4.73M | - | 2.67M | 2.57M | 1.51M | - | 3.08M | 4.11M | 2.05M | - | 1.38M | 1.48M | 1.42M | - | 1.95M | 1.96M | 1.71M | 2.51M | 2.27M | 2.49M | - | 1.58M | 1.46M | 2.37M | 1.89M | 2.90M | 2.10M | 3.11M | 2.52M | 2.88M | 2.82M | 1.87M | 1.59M | 1.06M | 2.14M | 2.71M | 2.76M | 2.04M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 7.71M | 0 | - | - | 0 | 0 | 428.03K | 164.99K | 0 | 16.14M | 500.00K | -2.85M | 11.20M | 1.98M |
| Operating Income | - | 3.88M | -10.68M | -20.48M | -18.38M | -19.19M | -21.22M | -11.33M | -12.90M | -18.00M | 3.15M | -12.12M | -17.93M | -1.16M | -10.37M |
| Net Income | -5.16K | 3.89M | -10.59M | -20.37M | -18.21M | -18.97M | -20.98M | -11.66M | -13.01M | -20.96M | -634.40K | -10.76M | -16.35M | 8.35K | -9.63M |
| Diluted EPS | - | 0.85 | -1.44 | -1.60 | -1.11 | -1.04 | -1.05 | -0.55 | -0.50 | -0.38 | -0.01 | -2.15 | -3.14 | - | -1.69 |
| R&D Expense | - | 2.28M | 5.12M | 15.48M | 12.58M | 8.08M | 11.00M | 6.46M | 7.47M | 9.75M | 7.67M | 8.56M | 10.18M | 7.35M | 8.58M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 32.44K | 5.57M | 46.11M | 27.99M | 45.38M | 27.34M | 25.33M | 20.85M | 19.66M | 25.35M | 52.48M | 37.54M | 23.00M | 22.51M | 17.01M |
| Total Equity | 1.30M | 5.32M | 44.82M | 26.36M | 41.99M | 26.02M | 18.98M | 9.43M | 6.29M | 15.34M | 45.57M | 35.63M | 20.37M | 21.00M | 14.48M |
| Cash & Equivalents | 8.57M | 5.38M | 45.26M | 27.67M | 20.01M | 5.56M | 3.21M | 8.08M | 9.73M | 19.22M | 2.95M | 3.15M | 4.77M | 6.21M | 5.21M |
| Long Term Debt | - | - | - | - | - | - | 0 | 6.93M | 3.81M | 2.26M | 1.67M | - | - | - | - |
| Total Liabilities | - | 250.03K | 1.28M | 1.63M | 3.39M | 1.33M | 6.35M | 11.42M | 13.37M | 10.01M | 6.91M | 1.91M | 2.63M | 1.51M | 2.53M |
| Current Liabilities | 7.61K | 212.81K | 1.28M | 1.63M | 3.39M | 1.33M | 6.35M | 4.49M | 4.96M | 6.58M | 5.62M | 1.68M | 2.63M | 1.51M | 2.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.29K | -3.18M | -8.59M | - | -15.36M | -18.28M | -16.70M | -12.08M | -11.67M | -15.30M | -4.41M | -11.97M | -11.87M | -1.22M | -9.76M |
| Investing Cash Flow | - | -12.32K | -1.21K | - | -25.02M | 3.23M | 3.13M | 11.29M | 3.00M | 3.89M | -43.78M | 14.29M | 13.08M | 2.45M | 5.89M |
| Financing Cash Flow | 30.24K | 0 | 48.48M | - | 32.72M | 605.87K | 11.23M | 10.65M | 10.32M | 20.90M | 26.92M | -2.13M | 404.57K | 209.34K | 2.87M |
| Capital Expenditure | - | -12.32K | -1.21K | -59.61K | -28.69K | -59.65K | -0 | -0 | - | - | -7.59K | -133.83K | -13.17K | -90.09K | - |
| Free Cash Flow | - | -3.19M | -8.59M | - | -15.38M | -18.34M | -16.70M | -12.08M | - | - | -4.42M | -12.10M | -11.88M | -1.31M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | 50.3% | - | - | - | - | - | -2,646.0% | -7,818.8% | - | 19.5% | -2,423.9% | 629.0% | -10.3% | -524.7% |
| Net Margin % | - | 50.4% | - | - | - | - | - | -2,724.1% | -7,883.7% | - | -3.9% | -2,151.7% | 573.6% | 0.1% | -487.1% |
| ROE % | -0.4% | 73.1% | -23.6% | -77.3% | -43.4% | -72.9% | -110.6% | -123.6% | -206.9% | -136.7% | -1.4% | -30.2% | -80.3% | 0.0% | -66.5% |
| ROCE % | - | 72.4% | -23.8% | -77.7% | -43.8% | -73.7% | -111.8% | -69.2% | -87.8% | -95.9% | 6.7% | -33.8% | -88.0% | -5.5% | -71.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Squadron Capital Management LLC | 9.83% | 810.00K | $1.79M |
| 2 | Ikarian Capital, LLC | 6.17% | 508.56K | $1.12M |
| 3 | Eversept Partners, LP | 3.58% | 294.99K | $651.92K |
| 4 | Vanguard Capital Management LLC | 2.80% | 230.82K | $510.12K |
| 5 | Acadian Asset Management. LLC | 2.07% | 170.42K | $376.62K |
| 6 | Boothbay Fund Management, LLC | 1.70% | 140.49K | $310.48K |
| 7 | Jane Street Group, LLC | 1.16% | 95.23K | $210.45K |
| 8 | Blackrock Inc. | 1.08% | 89.27K | $197.29K |
| 9 | Two Sigma Investments, LP | 1.03% | 84.89K | $187.60K |
| 10 | Citadel Advisors Llc | 0.99% | 81.22K | $179.50K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LPCN
Lipocine Stock Price Forecast. Should You Buy LPCN? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5zamxEYXNYeG1UalNWMUFKSHBzdG02YlV5SEZIUVZoV3lUZjhKcXdSQWZMVTJPSGU3TllDX2lpbG5VTzEyd1NJZg?oc=5" target="_blank">Lipocine Stock Price Forecast. Should You Buy LPCN?</a> <f…
LPCN Stock Crashes 78%— Here’s Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOOXh6T2J1bEtBVGlkem5TSnpkVFk5dm5lakRNaEgyNHdsWGN5X2VxbTBjU01pZms2VE5IX2VKcmtQZ1ptWUJDV2hRbm1wX3BlNjBmemthSVRpbDZKcnhhNnk1ZHJhU2tlQTE1WFJOYmY2NDY1TGRPM1hqaE1zQ0o0SGdvTDVzYllUbmlGMk…
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PR Newswire
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPWDk4U2hUQURyTXFKQm1zQUR3RVJNS3JBZzZiaUctUFZia1JxSWoxcEdYNFIwalg2blU2dlhyNG9Rb0ZoeF9Ydmo2SzlFVEpPNGlCT1UxMC1wR0dLTkRCQ1JRSXFPR3kwTnhkcnN1cWtvWTlIVmJDQWhoTnFoTlVwS3ByMWQ0aFlRTXBOWn…
Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE44NExXbHZ4eUl4cmZzU3Rlb2lPVjFNX0Y4RWI2SDZkblkxYlo5b2Vjd05QY1VFemJ0TDhpQko1eUJvLVhpcFg4MHU4OXZLWW12V3RrSE1B?oc=5" target="_blank">Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock…
$LPCN stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQLWJFV2VXcl82Q0F6Mlhkck4zb0xNdFlrYzRIbTZzeldTT2t1NXhGbXZpUzhvS0VnUlN4bk1KV291SDZncGloZWdZYkpoSGNaek9KLVR0YTJhdFZnN1gzY3lMX2RqQ3gyWF9KbHF4TzJ3ZVJyX3Y5NmMwV3BFYWllSlVjbHljUndMY2lic0…
Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNbjQ5cVhyUGhJZndjMDNSdzdTLVB0TmRjQVcxeEE4a1ZPdTVWQUNTNjZsbXBZcjU3YW55SG1zQjBaM21GWmU5VVdZMjkxN2JueHBNVWQxUy1oWVh4SzNVRjZTMExCX1pSMkdWN0ZNaTlLcUhDQUREamJDZTJQeEo0cTRobFhCUzFvcERueE…
LPCN — Frequently Asked Questions
What is the current share price of Lipocine Inc. (LPCN)?
As of 2026-09-19 21:16 PDT, Lipocine Inc. (LPCN) trades at $2.36 on NasdaqCM. Its 52-week range is $1.94 to $11.26.
What is the market capitalisation of LPCN?
Lipocine Inc. (LPCN) has a market capitalisation of $19.46M on NasdaqCM.
What is the P/E ratio of LPCN?
LPCN trades at a trailing price-to-earnings (P/E) ratio of -1.28. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.84.
What is the return on equity (ROE) of LPCN?
LPCN has a return on equity (ROE) of -60.94%. Its return on capital employed (ROCE) is -71.64%.
Is LPCN a good stock to buy?
This page provides a data-driven analysis of Lipocine Inc. (LPCN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.